Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05957367 · ClinicalTrials.gov registry record · Phase 1
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
A Phase 1 study of GIST, sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 14
- Study locations
NCT05957367: Recruiting Phase 1 study of GIST, sponsored by Deciphera Pharmaceuticals.
NCT05957367 is a Phase 1 study of GIST that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 94 participants, below the 124-participant average among 8 other GIST trials with a reported enrollment target (24% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05957367, a Phase 1 study of GIST, is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
Primary Outcome
Identify the observed adverse events and serious adverse events associated with inlexisertib in combination with other anticancer therapies.
Conditions Studied
Interventions
- DRUG Inlexisertib
- DRUG Ripretinib
Study Locations (14)
Other
- Antonie Van Leeuwenhoek Hospital - Amsterdam
- Radboudumc - Nijmegen
- Inselspital Universitätsklinikum Bern - Bern
California
- University of Southern California - Norris Comprehensive Cancer Center - Los Angeles
- UCLA Department of Medicine-Hematology/Oncology - Los Angeles
Florida
- Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- University of Massachusetts Worcester - Worcester
Michigan
- START Midwest - Grand Rapids
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
New York
- Memorial Sloan Kettering Cancer Center - Main Campus - New York
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT05957367 shows while recruiting
NCT05957367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 124-participant average among 8 other GIST trials with a reported enrollment target (24% lower).
The record links to 1 condition, with GIST appearing as the primary indexed condition, and to 2 interventions - of which Inlexisertib is the first listed.
NCT05957367 lists 14 locations in 11 states (Other, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05957367 about?
NCT05957367 is a clinical study titled "A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies". This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
What is the current status of trial NCT05957367?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2023-09-28. Estimated completion is 2029-03.
What conditions does trial NCT05957367 study?
This clinical trial studies the following conditions: GIST.
What interventions are being tested in trial NCT05957367?
The interventions under investigation include: Inlexisertib (DRUG), Ripretinib (DRUG).
Who is sponsoring clinical trial NCT05957367?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05957367 being conducted?
This trial has 14 study locations across California, Florida, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GIST
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05957367's enrollment target sits among peer trials
94 3rd of 8 higher than 6 of 8 other GIST trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other GIST trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RECRUITING · Phase 1
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
-
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI